When mantle cell lymphoma stops responding to treatment, the options narrow fast. This rare but aggressive form of non-Hodgkin lymphoma tends to come back after initial therapy, and once it resists BTK inhibitors like ibrutinib or zanubrutinib, many patients are left with few viable paths forward. On May 13, 2026, the FDA granted accelerated approval to sonrotoclax (brand name BEQALZI), a once-daily oral pill that targets the disease through a completely different mechanism. It is the first and only BCL-2 inhibitor approved for relapsed or refractory mantle cell lymphoma.
In the pivotal trial, 52 percent of patients responded, and those responses lasted a median of 15.8 months. For people who have already cycled through multiple rounds of chemotherapy, immunotherapy, and BTK-targeted drugs, those numbers represent a meaningful new option. But the approval came through the FDA’s accelerated pathway, which means a larger, randomized trial must still confirm that the drug extends survival.
How sonrotoclax attacks the cancer’s survival machinery
Every cell in the body carries built-in self-destruct programming called apoptosis. A family of proteins governed by BCL-2 acts as the gatekeeper, balancing signals that say “live” against signals that say “die.” A peer-reviewed review in Oncogene describes how BCL-2 family members control this switch and why the balance matters so much in cancer biology. In mantle cell lymphoma, cancer cells flood themselves with BCL-2 protein, essentially jamming the survival switch in the “on” position so the cell never receives the signal to die.
Sonrotoclax binds directly to BCL-2 and disables that protection. With the survival signal blocked, the cancer cell’s own death machinery kicks back in, triggering apoptosis. This is fundamentally different from how BTK inhibitors work, which is why sonrotoclax can still be effective in patients whose lymphoma has already learned to evade BTK-targeted drugs.
The approach is not entirely new to oncology. Venetoclax, another BCL-2 inhibitor, has been used for years in chronic lymphocytic leukemia and certain types of acute myeloid leukemia. But venetoclax does not carry an FDA indication for mantle cell lymphoma, which makes sonrotoclax the first drug in its class to reach this specific patient population through a regulatory approval.
What the pivotal trial showed
The approval is based on results from a single-arm trial called BGB-11417-201 (registered as NCT05471843), which enrolled adults with relapsed or refractory mantle cell lymphoma who had received at least two prior lines of therapy, including a BTK inhibitor. According to BeOne Medicines’ SEC filing, the key findings at a median follow-up of 11.9 months were:
- Overall response rate: 52 percent
- Complete response rate: 16 percent
- Median time to response: 1.9 months
- Median duration of response: 15.8 months
These are surrogate endpoints, meaning they measure tumor shrinkage and how long that shrinkage lasts rather than directly measuring whether patients live longer. For the FDA’s accelerated approval pathway, surrogate endpoints are sufficient when they are “reasonably likely to predict clinical benefit,” as the agency’s own program description explains. But they are not proof of a survival advantage.
Context helps frame what these numbers mean. Mantle cell lymphoma that has relapsed after BTK inhibitor therapy is notoriously difficult to treat. Published response rates for salvage regimens in this setting vary widely depending on the agent and patient population, and many responses are short-lived. A 52 percent response rate with durability exceeding a year stands out in that landscape, though the absence of a comparator arm means the results cannot be directly measured against an alternative treatment.
What is still unknown
The accelerated approval pathway is designed to get promising drugs to patients with serious diseases faster, but it comes with strings attached. BeOne Medicines is required to run a confirmatory randomized trial, and that study is already underway. Called CELESTIAL-RRMCL and listed on ClinicalTrials.gov, it compares sonrotoclax plus zanubrutinib against placebo plus zanubrutinib in relapsed or refractory mantle cell lymphoma patients. This head-to-head design will test whether adding BCL-2 inhibition to a BTK inhibitor produces better progression-free survival and overall survival than the BTK inhibitor alone. If the trial fails to confirm a meaningful benefit, the FDA has the authority to withdraw the approval.
Several other gaps remain in the publicly available evidence as of late May 2026. Neither the FDA announcement nor the SEC filing includes full safety tables or rates of severe adverse events from BGB-11417-201. This is a notable omission for a BCL-2 inhibitor, because drugs in this class carry known risks. Tumor lysis syndrome, a potentially dangerous condition in which dying cancer cells release their contents into the bloodstream faster than the body can clear them, is a well-documented concern with BCL-2 inhibition and typically requires a careful dose ramp-up schedule to manage. Cytopenias (low blood cell counts) and serious infections are also risks associated with this drug class. Without published grade 3 and grade 4 toxicity data from the pivotal trial, clinicians and patients are working with an incomplete picture of the drug’s safety profile.
There is also no published comparison between sonrotoclax and CAR-T cell therapy, which received FDA approval for relapsed mantle cell lymphoma in 2020 (brexucabtagene autoleucel). CAR-T is a one-time infusion rather than a daily pill, and it works through a completely different mechanism, reprogramming a patient’s own immune cells to hunt lymphoma. For patients weighing their options after BTK inhibitor failure, understanding how these two approaches compare in terms of efficacy, toxicity, and accessibility will be an important question that current data cannot yet answer.
How sonrotoclax fits into a shrinking treatment sequence
For the roughly 4,000 to 5,000 Americans diagnosed with mantle cell lymphoma each year, the treatment landscape has shifted significantly over the past decade with the arrival of BTK inhibitors and CAR-T therapy. But each new line of treatment tends to produce shorter remissions, and patients who have exhausted both BTK inhibitors and other standard approaches face a genuine clinical dead end. Sonrotoclax fills a specific gap: it offers an oral, outpatient treatment that targets a different vulnerability in the cancer cell, without requiring the infrastructure of a CAR-T center or the intensity of reinduction chemotherapy.
The practical appeal of a daily pill should not be underestimated. Unlike CAR-T therapy, which requires leukapheresis, manufacturing time, hospitalization, and monitoring for severe side effects like cytokine release syndrome, sonrotoclax can be prescribed and managed in a standard oncology clinic. For older patients or those with comorbidities that make intensive treatments risky, that difference in logistics can be as important as the difference in efficacy data.
The accelerated approval label, however, is a signal to interpret carefully. It means the FDA saw enough promise to make the drug available now, but not enough evidence to call the case closed. The CELESTIAL-RRMCL trial will determine whether sonrotoclax earns a permanent place in the treatment sequence or whether its regulatory status is narrowed. Until those randomized results arrive, sonrotoclax occupies an unusual position: a drug with a clear biological rationale, encouraging early response data, and a 15.8-month median duration of response, but without the survival proof that would make its role definitive.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
